WAVE LIFE SCIENCES LTD

NASDAQ: WVE (Wave Life Sciences Ltd.)

Kemas kini terakhir: 01 Dec, 6:30PM

15.10

0.11 (0.73%)

Penutupan Terdahulu 14.99
Buka 14.89
Jumlah Dagangan 623,952
Purata Dagangan (3B) 1,879,433
Modal Pasaran 2,303,052,032
Harga / Jualan (P/S) 30.89
Harga / Buku (P/B) 14.20
Julat 52 Minggu
3.50 (-76%) — 16.74 (10%)
Tarikh Pendapatan 12 Nov 2024
Margin Keuntungan -265.84%
Margin Operasi (TTM) 832.66%
EPS Cair (TTM) -1.12
Pertumbuhan Hasil Suku Tahunan (YOY) -10.90%
Jumlah Hutang/Ekuiti (D/E MRQ) 18.17%
Nisbah Semasa (MRQ) 1.90
Aliran Tunai Operasi (OCF TTM) -140.62 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -7.89 M
Pulangan Atas Aset (ROA TTM) -34.04%
Pulangan Atas Ekuiti (ROE TTM) -243.82%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Wave Life Sciences Ltd. Menaik Menaik

AISkor Stockmoo

-1.0
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -5.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata -1.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
WVE 2 B - - 14.20
ARGX 37 B - - 8.52
ALNY 32 B - - 972.68
ROIV 9 B - 2.17 1.63
INCY 13 B - 771.11 4.19
SMMT 13 B - - 28.58

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Mid Growth
% Dimiliki oleh Orang Dalam 15.04%
% Dimiliki oleh Institusi 78.72%
Julat 52 Minggu
3.50 (-76%) — 16.74 (10%)
Julat Harga Sasaran
15.00 (-0%) — 36.00 (138%)
Tinggi 36.00 (Truist Securities, 138.41%) Beli
Median 22.00 (45.70%)
Rendah 15.00 (RBC Capital, -0.66%) Pegang
Purata 21.60 (43.05%)
Jumlah 9 Beli, 1 Pegang
Harga Purata @ Panggilan 14.32
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Mizuho 21 Nov 2024 22.00 (45.70%) Beli 14.35
HC Wainwright & Co. 13 Nov 2024 22.00 (45.70%) Beli 15.69
31 Oct 2024 22.00 (45.70%) Beli 13.71
Truist Securities 12 Nov 2024 36.00 (138.41%) Beli 15.89
B. Riley Securities 04 Nov 2024 22.00 (45.70%) Beli 13.79
03 Oct 2024 19.00 (25.83%) Beli 8.50
RBC Capital 21 Oct 2024 15.00 (-0.66%) Pegang 15.11
04 Oct 2024 7.00 (-53.64%) Pegang 8.41
JP Morgan 17 Oct 2024 17.00 (12.58%) Beli 14.61
27 Sep 2024 13.00 (-13.91%) Beli 8.29
Leerink Partners 16 Oct 2024 22.00 (45.70%) Beli 14.90
Raymond James 16 Oct 2024 22.00 (45.70%) Beli 14.90
Wells Fargo 16 Oct 2024 22.00 (45.70%) Beli 14.90
Jones Trading 25 Sep 2024 16.00 (5.96%) Beli 9.01
Papar semua

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
16 Dec 2024 Pengumuman Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
26 Nov 2024 Pengumuman Wave Life Sciences to Present at Upcoming Investor Conferences
15 Nov 2024 Pengumuman Wave Life Sciences to Present at Jefferies London Healthcare Conference
12 Nov 2024 Pengumuman Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
04 Nov 2024 Pengumuman Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024
30 Oct 2024 Pengumuman Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
16 Oct 2024 Pengumuman Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
16 Oct 2024 Pengumuman Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
01 Oct 2024 Pengumuman Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares 
30 Sep 2024 Pengumuman Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
25 Sep 2024 Pengumuman Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
24 Sep 2024 Pengumuman Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
24 Sep 2024 Pengumuman Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2024 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda